4meSM
Bluelighter
I think they introduce a known P-gp substrate, meaning a molecule which is know to be excreted from the cell by P-gp, and then they add different drugs (like norbupe) to observe if the standard substrate is able to get out (and if so, how much manages to get out compared to the control test).Aaah okay. So what exactly do they mean when they say norbuprenorphine inhibited P-gp? I always thought that meant is stopped P-gp from working. If norbupe inhibits it, wouldn't that mean norbupe could get through? Or if P-gp much more apparent and stronger in the blood-brain-barrier perhaps?
If adding norbupe decreases or prevents the standard substrate from getting out of the cell then they conclude norbupe must be inhibiting P-gp.
Or something along those lines, it's not an in-vivo test or anything like that, I think they use some specific mutant cells (like dog cells with some human genes) to run those tests.
I know some stuff about enzymes but those kinds of studies are really not my forte

I read somewhere else that norbupe is a actually a P-gp substrate and it's thrown OUT of the brain, I mentioned it in my second post.
So that may be the reason why the study you shared said it's an inhibitor, not necessarily because it prevents P-gp from doing anything, but perhaps because P-gp is too busy getting norbupe out of the cell which means it wouldn't be able to also get the other standard substrate out (in short, it would prefer norbupe over other molecules).
But I would have to read the whole study, which I haven't lol.
BUT, norbupe might be able to cross the BBB to go INTO the brain via a different mechanism/transporter, I don't know but I think it's possible.
Anyway, seems like everyone agrees with low doses being better, if you want to get the most out of it.
Last edited: